Links

Tools

Export citation

Search in Google Scholar

Molecular genetics and patient management of multiple endocrine neoplasia type 1

Journal article published in 2001 by R. V. Thakker ORCID
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant disorder characterized by the combined occurrence of tumours of the parathyroids, pancreatic islet cells and anterior pituitary. Other MEN-1-associated tumours include angiofibromas, collagenomas, lipomas, carcinoids and adrenocortical tumours. The MEN-1 gene, which represents a putative tumour suppressor gene, was identified in 1997, and over 340 mutations have been reported in MEN-1 families, patients with non-familial MEN-1, families with isolated primary hyperparathyroidism and those with sporadic non-MEN-1 endocrine tumours. The mutations are scattered throughout the nine exons that encode a 610 amino acid nuclear protein (MENIN), which interacts with the transcriptional factor JunD. These recent developments have made it possible to consider genetic screening for this inherited disorder.